OPEN ACCESS
ISSN: 2835-9496
Frasier K, et al. (2024): 461
DOI: 10.47991/2835-9496/AJCMR-139

Review Article
American Journal of Clinical and Medical Research

Telemedicine and Remote Monitoring in Purpura Fulminans Critical Care: Enhancing Early Detection and Intervention

Kelly Frasier, DO, MS[1*], Grace Herrick, BA[2], Mahnoor Mukarram, MS[3], Turkan Banu Karatas, BA[4], Vivian Li, DO, MMS[1], Haily Fritts, BS[5]

[1]Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY
[2]Alabama College of Osteopathic Medicine, Dothan, AL
[3]Midwestern University Arizona College of Osteopathic Medicine, Glendale, AZ
[4]Emory University School of Medicine, Atlanta, GA
[5]Idaho College of Osteopathic Medicine, Meridian, ID

***Corresponding author:** Kelly Frasier, Nuvance Health/Vassar Brothers Medical Center, Poughkeepsie, NY. Email: kellymarie frasier@gmail.com

Citation: Frasier K, Herrick G, Mukarram M, Karatas TB, Li V, et al. (2024) Telemedicine and Remote Monitoring in Purpura Fulminans Critical Care: Enhancing Early Detection and Intervention. Ameri J Clin Med Re: AJCMR-139.

Received Date: 13 June, 2024; **Accepted Date:** 18 June, 2024; **Published Date:** 24 June, 2024

Abstract

Purpura fulminans is a severe and rapidly progressing condition that necessitates immediate medical intervention to prevent high mortality and morbidity. Traditional management strategies involve intensive in-person monitoring and timely therapeutic interventions, which can be challenging due to the rapid progression and the need for specialized care. This study explores the integration of telemedicine and remote monitoring technologies in the critical care of purpura fulminans, focusing on enhancing early detection and timely intervention. Previous research has demonstrated the efficacy of telemedicine in various critical care settings, improving patient outcomes through continuous monitoring and rapid response capabilities. However, its application specifically to purpura fulminans remains underexplored. We propose a novel framework utilizing wearable sensors, artificial intelligence (AI) algorithms with real-time data analytics, and teleconsultation to monitor key physiological parameters indicative of purpura fulminans progression. This approach aims to facilitate earlier recognition of critical symptoms and faster initiation of appropriate treatments, potentially improving survival rates and reducing complications. Future research should investigate the implementation challenges, cost-effectiveness, and patient outcomes associated with this technology-driven model, as well as explore advancements in sensor accuracy, data integration, and telehealth infrastructure to optimize remote critical care for purpura fulminans and other rapidly evolving dermatological critical conditions.

Introduction

Purpura fulminans (PF) is a life-threatening condition characterized by sudden onset of skin necrosis and disseminated intravascular coagulation (DIC). PF is a rare condition that was initially documented in 1984. While it predominantly manifests in children, it can also occur in adults. PF is typically categorized into one of three forms based on its triggering mechanism: (1) neonatal purpura fulminans, characterized by a hereditary deficiency of protein C, protein S or antithrombin III, (2) idiopathic purpura fulminans, which follows a febrile illness and is associated with protein S deficiency, and (3) acute infectious purpura fulminans, which is the most common type [1]. It is often associated with severe infections, particularly meningococcemia, and can rapidly lead to multiple organ failure if not promptly treated [2]. The urgency and complexity of PF management necessitates immediate medical intervention and continuous monitoring to mitigate the high mortality and morbidity associated with this condition. Traditional management relies heavily on in-person medical care, which poses significant challenges due to the rapid progression of symptoms and the need for specialized expertise in intensive care units (ICUs) [3]. Consequently, there is a pressing need for innovative approaches to improve early detection and timely intervention for patients presenting with PF.

Recent advancements in telemedicine have shown promising results in various critical care settings. Telemedicine involves the use of electronic communication and information technologies to provide and support healthcare when distance separates participants [4]. This technology has revolutionized healthcare delivery by enabling continuous patient monitoring, rapid response to clinical changes, and enhanced access to specialist consultations. In critical care, telemedicine has shown to improve patient outcomes, reduce ICU length of stay, and decrease healthcare costs [5]. However, the utilization of telemedicine in the management of PF has not been thoroughly investigated, underscoring its potential for significant impact on patient care and health outcomes.

The integration of telemedicine with remote monitoring technologies offers a novel approach to managing PF. Wearable sensors and real-time data analytics can provide continuous, non-invasive monitoring of key physiological parameters such as blood pressure, heart rate, oxygen saturation, and coagulation markers [6]. These technologies can alert healthcare providers to early signs of deterioration, allowing for timely intervention. Teleconsultation can facilitate rapid communication between on-site healthcare providers and remote specialists, ensuring that patients receive expert care even in resource-limited settings [7]. This integrated approach has the potential to enhance early detection of PF and improve patient outcomes by enabling faster initiation of appropriate treatments.

Although the potential advantages of telemedicine and remote monitoring in PF care are significant, several barriers must be addressed in order to fully harness their potential. Implementation barriers include the need for robust telehealth infrastructure, reliable internet connectivity, and training for healthcare providers in the use of new technologies [8]. Additionally, issues related to data security, patient privacy, and the accuracy of remote monitoring devices must be carefully managed [9]. Cost-effectiveness is another critical consideration, as the initial investment in telemedicine infrastructure and wearable sensors may be substantial. Evaluating the long-term benefits and return on investment will be essential for widespread adoption of these technologies.

Future research should focus on addressing these challenges and evaluating the effectiveness of telemedicine and remote monitoring in PF care. Studies should investigate the impact of these technologies on patient outcomes, including mortality, morbidity, and quality of life. Additionally, research should explore advancements in sensor technology to improve the accuracy and reliability of remote monitoring. Data integration and interoperability between different telehealth systems will also be crucial to optimize care delivery. By addressing these areas, future research can pave the way for the successful implementation of a technology-driven model for PF care, ultimately improving patient outcomes and reducing the burden on healthcare systems.

Overview of Standard Approaches to Managing Purpura Fulminans

Management strategies for purpura fulminans are multifaceted, and mainly focus on antimicrobial therapy, supportive care, and hemodynamic support. PF is most commonly associated with severe bacterial infections caused by Neisseria meningitidis. Other bacterial pathogens, such as Streptococcus pneumoniae and Staphylococcus aureus, have also been identified as culprits to triggering PF. These infections can result in sepsis and disseminated intravascular coagulation (DIC), leading to the rapid progression of PF [13]. Antimicrobial therapy is therefore crucial in the current management of PF as well, particularly in cases where PF is secondary to sepsis [14]. Prompt initiation of broad-spectrum antibiotics is essential to combat the underlying infection that often triggers PF [14]. Empirical antibiotic regimens typically include a combination of agents to cover a broad range of potential pathogens, including Gram-positive, Gram-negative, and anaerobic bacteria, but the approach varies from patient to patient. Antimicrobial therapy is tailored to the identified pathogens after culture and sensitivity results of bacteria become available, as well as their resistance profiles. Early intervention with appropriate antimicrobial therapy is vital to controlling the infectious source and mitigating the inflammatory cascade that contributes to the progression of PF.

Supportive care for PF includes aggressive fluid resuscitation and transfusion of blood products to manage coagulopathies and prevent multiorgan failure. Initial fluid resuscitation typically involves the administration of cryoprecipitates to restore intravascular volume and control bleeding. Laboratory assessments, including a full blood count, fibrinogen and fibrin degradation products, prothrombin time (PT), activated partial thromboplastin time (aPTT), and platelet count, should be regularly monitored to track the progression of PF [10]. To mitigate the thrombocytopenia and abnormal coagulation seen with PF associated DIC, guidelines recommend that fresh frozen plasma (FFP) containing crucial clotting factors, fibrinogen-rich cryoprecipitate, and platelet transfusions, be administered in cases of persistent PF [11]. One report of idiopathic PF also recommends patients presenting with protein S autoantibodies to promptly receive treatment with plasmapheresis with intravenous immunoglobulin (IVIG) [12]. Patients suffering from PF often suffer from a deficiency of procoagulant and anticoagulant factors, and require supportive care including protein C, protein S, and antithrombin III [10]. The use of these anticoagulant factors has shown a reduction in skin necrosis, but are only recommended for PF patients with a low risk of bleeding [10,11]. The intricate and variable nature of PF, in conjunction with the diverse treatment options, illustrates the challenging aspect of managing this condition and the complex decisions physicians face in the treatment of this disease.

Finally, hemodynamic support aims to stabilize the patient's blood pressure and ensure adequate perfusion of vital organs. Vasopressors, such as norepinephrine, are often the first-line agents used to manage septic shock, a common complication of PF [15]. Norepinephrine acts primarily on alpha-adrenergic receptors to induce vasoconstriction and increase systemic vascular resistance, thereby raising blood pressure. Inotropic agents like dobutamine may also be used to enhance cardiac output by increasing myocardial contractility, particularly in patients with concomitant cardiac dysfunction [15]. Continuous monitoring of hemodynamic parameters, including arterial blood pressure, central venous pressure (CVP), and cardiac output, is critical to guiding the titration of these medications [16]. The goal is to maintain adequate perfusion pressures to vital organs while avoiding excessive vasoconstriction that could exacerbate tissue ischemia [16].

Despite these well-established guidelines, challenges and limitations still persist in effectively managing and treating PF. A significant issue is the potential delay in diagnosis, given the rapid progression of PF, and the nonspecific nature of early symptoms, leading to critical time lost in initiating treatment. Supportive care necessitates continuous and intensive monitoring to manage fluid balance and coagulopathies effectively, which can be resource-intensive and challenging in acute care settings [17]. The need for frequent laboratory testing to monitor coagulation parameters, electrolyte levels, and organ function can strain laboratory resources and result in delayed decision making. The increasing prevalence of antibiotic resistance complicates antimicrobial therapy, necessitating timely adjustments based on culture results, which unfortunately take days to process [18]. Hemodynamic support requires the precise titration of medications to maintain stability, which can be difficult in patients with rapidly fluctuating clinical status, further complicating management [19]. Additionally, the risk of vasopressor-induced peripheral ischemia is a significant concern, necessitating careful balance between adequate perfusion and avoiding further tissue damage [19].

The advent of AI technology presents a valuable opportunity to enhance these approaches, addressing existing limitations and barriers, and paving the way for improved patient outcomes. The potential of AI in early diagnosis, optimized treatment, and precise hemodynamic support underscores the need for continued investment and research in this promising field. By leveraging AI, healthcare providers can improve the speed and accuracy of PF management, ultimately saving lives and reducing the burden on healthcare systems. The aforementioned challenges prompt and guide our exploration of a novel three-pronged approach to managing PF, which includes the integration of wearable sensors, machine learning algorithms with real-time data analytics, and teleconsultation. We discuss specific examples of sensors and AI algorithms that have been studied and have the potential to be used to improve the treatment and management of PF. Overall, wearable sensors provide accurate and abundant data and lab values necessary for patient monitoring. Machine learning algorithms can integrate data from the wearable sensors to identify subtle signs and changes that may be missed by clinicians. Lastly, teleconsultation between physicians, along with notifications from sensors and algorithms, helps to reduce the burden of decision-making.

The Role of AI Technology in Addressing Management Challenges and Enhancing Support

AI Integrated Antimicrobial Therapy

The integration of AI has the potential to benefit patients with PF by addressing the increasing challenges of antibiotic resistance. One study, using the AI platform *IDentif.AI*, was able to quickly develop and refine effective combination therapies for patients affected by drug-resistant nontuberculous mycobacteria [18]. This study found that *IDentif.AI* was successful in creating combination therapies for multi-drug resistant bacteria. Applying this technology with PF patients could yield promising results in managing the condition effectively. Wearable sensors provide the ability to continuously monitor signs of infection, such as elevated temperature and increased heart rate. Sensors capable of detecting more specific biochemical markers of infection, like procalcitonin or C-reactive protein, are already being constructed and enhance early detection of infection as well [20]. AI-driven analytics integrate sensor data with electronic health records (EHR) to rapidly identify patterns indicative of sepsis or other infections [20]. This integration facilitates the early identification of causative pathogens and their resistance profiles, using information from prior similar cases and current patient-specific data.

Additionally, techniques such as genomic sequencing and AI-driven pattern recognition significantly shorten the time required to identify causative pathogens and their resistance profiles [21]. One genomic sequencing system, Ion Torrent PGM, has been evaluated for accuracy and quality, and has proven to have good performance with identifying pathogens [21]. Teleconsultation allows infectious disease specialists to review real-time data and provides guidance on antimicrobial therapy. Studies have emphasized that teleconsultations with shared-decision making, specifically antibiotic therapy, can be used to help educate patients on antibiotic resistance [22]. This enables the initiation of targeted antibiotic therapy based on predictive analytics before culture results are even confirmed, in addition to quick adjustments based on real-time feedback. Integrating AI into the management of PF through supportive care, antimicrobial therapy, and hemodynamic support offers the potential to significantly improve patient outcomes by enhancing the precision, timeliness, and efficiency of interventions.

AI Integrated Supportive Care

Wearable sensors have the potential to significantly enhance supportive care by optimizing fluid management and transfusion protocols [23]. Due to the fact that there are different types of non-invasive sensors, such as sweat, tears, interstitial fluid, urine sensors, the advantages and challenges of each type of sensor could be evaluated on a case by case basis to use with PF patients [23]. This is an added level of personalized and tailored care for these at-risk patients. Combining sensor data with AI algorithms minimizes the risk of fluid overload or under-resuscitation. For instance, AI algorithms can predict the optimal volume of fluids or blood products needed based on dynamic changes in vital signs and laboratory values [24]. This AI-driven diagnostic tool can also aid in the early detection of PF by analyzing patient data for patterns indicative of the disease. The exploration of the Protégé Web Ontology Language tool paired with Java has been investigated and demonstrated to predict drug-induced side effects and improve diagnostic accuracy of conditions [25]. This tool serves as another example of tailoring supportive drug regimen care for patients with PF. While sensors can analyze the PF patient's hemodynamic data in real-time, the algorithms can predict fluid responsiveness and guide the precise administration of intravenous fluids [26]. AI continuously monitors parameters such as blood pressure, heart rate, and urine output, dynamically adjusting fluid administration to avoid both fluid overload and hypovolemia [26].

Additionally, AI can assist in managing blood product transfusion by integrating data from laboratory results and clinical parameters to determine the optimal timing and quantity of transfusions [24]. Predictive analytics can anticipate drops in hemoglobin or platelet counts, allowing for preemptive measures to maintain homeostatic balance [27]. A hand held diffuse reflectance spectroscopy to measure hemoglobin levels recently demonstrated a strong correlation with invasive reference methods [27]. Wearable sensors continuously monitor vital signs such as heart rate, blood pressure, oxygen saturation, and temperature. When data from these wearable sensors in PF patients is combined with machine learning algorithms, early signs of hemodynamic instability and coagulopathy can be detected. For example, sudden changes in heart rate variability or drops in blood pressure could trigger alerts for potential fluid resuscitation needs [26]. Healthcare providers can remotely access this patient data through secure teleconsultation platforms, enabling early detection of concerning trends. This prompts immediate teleconsultation with specialists, allowing for timely adjustments to fluid therapy and blood product transfusions.

AI Integrated Hemodynamic Support

Advanced sensors can continuously monitor hemodynamic parameters such as central venous pressure, cardiac output, and arterial pressure waveforms. These monitors can also adjust vasopressor and inotropic therapy [28]. For example, GPCR Activation-Based NE (GRABNE) sensors have been developed to assess cell-specific regulation of noradrenergic transmission across various physiological and pathological conditions [29]. This robust imaging-based tool could be crucial for understanding and managing the complex autonomic dysregulation and stress responses associated with PF. Algorithms then analyze patient data to predict changes in hemodynamic status, allowing for proactive adjustments to medication dosages [30]. AI-driven systems facilitate better communication and coordination among healthcare teams, ensuring that critical information is promptly shared and acted upon. Automated alerts and decision support tools guide clinicians in titrating vasopressors and inotropes to optimal levels, reducing the risk of under- or over-treatment [30]. AI technology in managing PF addresses many existing challenges, ultimately improving patient outcomes through more timely, accurate, and efficient care. Predictive models suggest optimal dosages and combinations of vasopressors and inotropes, adjusting in real-time to maintain stable perfusion [30]. Clinicians can use teleconsultation to receive updates in real-time on hemodynamic status and consult with intensivists or cardiologists [30]. This collaboration facilitates rapid adjustments to hemodynamic support strategies, ensuring that interventions are promptly tailored to the patient's evolving condition.

Discussion

The integration of telemedicine and remote monitoring technologies in the management of purpura fulminans represents a transformative approach with the potential to significantly improve patient outcomes. Traditional management of PF involves continuous in-person monitoring and rapid therapeutic interventions, which can be logistically challenging and resource-intensive [2]. By leveraging telemedicine, healthcare providers can remotely monitor patients' physiological parameters in real-time, thereby enabling earlier detection of critical changes and prompt intervention. Telemedicine may allow for the timely recognition of critical symptoms, including the sudden onset of purpuric lesions and systemic signs of sepsis, which may facilitate earlier initiation of imperative treatment protocols [31]. This capability is particularly vital in the context of PF, where delays in recognizing and treating the condition can lead to severe complications and increased mortality [3].

The implementation of wearable sensors and real-time data analytics forms the backbone of this telemedicine framework. Wearable sensors can continuously track vital signs such as heart rate, blood pressure, oxygen saturation, and coagulation profiles, providing a comprehensive picture of a patient's condition. Real-time data analytics can then process this information, identifying patterns and anomalies indicative of PF progression. These analytics can trigger alerts to healthcare providers, ensuring that they are immediately informed of any concerning changes. This proactive approach facilitates timely medical interventions, which are crucial in mitigating the rapid deterioration associated with PF [7].

Teleconsultation further enhances the efficacy of this telemedicine model by enabling seamless communication between on-site healthcare providers and remote specialists. PF requires specialized knowledge for effective management, and teleconsultation can bridge the gap between general healthcare providers and experts in critical care or hematology [4]. This collaboration ensures that patients receive high-quality care regardless of their geographical location. Additionally, teleconsultation can support decision-making processes, allowing for the rapid adjustment of treatment plans based on real-time patient data and expert recommendations [8].

Comparing the efficacy of telemedicine and remote monitoring with traditional in-hospital care demonstrates a complementary relationship. While traditional care provides direct, hands-on intervention, telemedicine assists in extending the reach of healthcare providers, enabling continuous patient engagement and monitoring. A hybrid approach, combining both methods, can leverage the strengths of each to optimize patient outcomes, particularly in managing acute and critical conditions like PF [32]. Clinical evidence supports the efficacy of telemedicine and remote monitoring in enhancing patient outcomes in critical care settings. For instance, Young et al. demonstrated that the use of remote monitoring in critical care units led to a significant reduction in response times and improved clinical outcomes, particularly in conditions requiring rapid intervention like PF [33]. Furthermore, case studies have also highlighted instances where early intervention, guided by telemedicine insights, have prevented severe complications and improved patient survival rates [34].

The future of telemedicine and remote monitoring in critical care is promising with advancements in both AI and machine learning revolutionizing medicine. AI-driven predictive analytics can enhance the early detection of PF by analyzing complex data patterns and quickly identifying high-risk patients [35]. These analyses may detect and identify crucial changes in a patient's clinical course, potentially even before clinicians are able to do so. Personalized medicine approaches, supported by these technologies, can additionally tailor interventions to individual patient needs, potentially improving patient prognosis and overall outcomes [36]. The integration of advanced monitoring systems into standard care protocols may transform the management of critical conditions, making early detection and timely intervention much more feasible and effective [37].

Despite the promising benefits, several challenges must be addressed to optimize the integration of telemedicine and remote monitoring in PF care. One significant barrier is the establishment of a prominent telehealth infrastructure capable of supporting continuous data transmission and real-time analytics [9]. Issues pertaining to data security and patient privacy are of paramount importance as well, necessitating strong encryption and compliance with HIPAA regulations to ensure the confidentiality of sensitive patient information [9]. Reliable internet connectivity is essential, particularly in remote or resource-limited settings where traditional healthcare resources may be scarce. Furthermore, training healthcare providers to effectively use telemedicine technologies and interpret the data generated by wearable sensors is critical to ensuring the successful implementation of this approach [5]. Addressing these logistical and educational challenges is vital to achieving the full potential of telemedicine in PF management.

Another area of focus is supporting the staffing of telemedicine systems. Rural or otherwise underserved areas are limited in their number of trained specialists, in which case telemedicine can offer great support, perhaps by partnering up with nearby large academic centers. This would however necessitate providing staffing an adequate number of trained specialists who are willing and capable of delivering the telemedicine services. This might trigger new challenges within the physician workforce, highlighting the shortage of healthcare providers that the telemedicine system would require. While establishment and funding of telemedicine systems seems challenging, they are able to provide great potential for improved patient care and reduced patient complications in underserved areas where access to specialists and prompt diagnosis are not easily accessible. Therefore, further investment, feasibility studies, and policy changes are encouraged to ensure the health care system delivers its promises.

Future research should focus on evaluating the long-term impact of telemedicine and remote monitoring on patient outcomes in PF. Clinical trials and observational studies are needed to assess the efficacy of these technologies in reducing mortality, morbidity, and healthcare costs [3]. Additionally, research should explore advancements in sensor technology to improve the accuracy and reliability of remote monitoring devices. Innovations in data integration and interoperability between different telehealth systems will also be crucial to optimizing care delivery. By addressing these research areas, we can develop a comprehensive, technology-driven model for managing PF that improves patient outcomes and enhances the efficiency of healthcare systems.

Areas for Future Research

The implementation of telemedicine and remote monitoring in purpura PF care is a promising advancement, yet it necessitates extensive future research to address several critical areas. First, clinical trials are essential to establish the efficacy and safety of telemedicine interventions in PF management. Such studies should focus on comparing patient outcomes between traditional in-person care and telemedicine-supported care, specifically looking at mortality rates, complication rates, and overall patient recovery [3]. These trials should also consider various demographic factors, such as age, comorbidities, and geographic location, to determine if certain patient populations benefit more from telemedicine approaches.

Additionally, there is a need for research into the optimization of wearable sensor technology used in remote monitoring. Current sensors track vital signs such as heart rate, blood pressure, and oxygen saturation; however, advancing the technology to measure additional biomarkers related to coagulation and inflammation could significantly enhance early detection of PF exacerbations [5]. Future research should focus on improving sensor accuracy, reducing latency in data transmission, and ensuring the durability and comfort of wearable devices. Integrating artificial intelligence (AI) and machine learning algorithms to analyze the vast amounts of data generated by these sensors can also help in predicting patient deterioration and recommending timely interventions [36].

Another critical area for future research is the development and evaluation of telehealth infrastructure. Studies should explore the most effective ways to implement and scale telemedicine solutions in diverse healthcare settings, particularly in resource-limited and rural areas where access to specialized care is often limited [9]. Research should also address the technical aspects of telehealth, such as data security, patient privacy, and system interoperability to ensure that telemedicine platforms can seamlessly integrate with existing healthcare systems and electronic health records (EHRs) [8]. Pilot programs and case studies documenting the implementation process, challenges faced, and solutions developed can provide valuable insights for broader adoption.

Finally, the economic implications of telemedicine and remote monitoring in PF care warrant thorough investigation. Cost-effectiveness analyses comparing traditional care with telemedicine-supported care should consider not only the initial setup and operational costs but also the long-term financial benefits, such as reduced hospital readmissions, shorter ICU stays, and lower healthcare costs due to earlier intervention. Research should also examine the potential cost savings for patients, such as reduced travel expenses and time away from work. These economic studies can help policymakers and healthcare providers make informed decisions about investing in telemedicine infrastructure and integrating these technologies into standard care protocols.

In addition to the economic implications and benefits, another area of exploration needs to focus on the insurance aspect of these services. Clear guidelines and policies are needed on the insurance claim and coverage processes. Future policy recommendations and advocacy are also needed in order to ensure collaboration from insurance companies when offering patients telemedicine services as well as technology use for items such as wearable sensors. While these technologies offer benefits in lowering certain costs, such as shorter hospitalizations, there should be a similar expectation in accessing these proposed technologies in order to provide patients with an attainable service.

Clinical Applications

The clinical applications of telemedicine and AI-integrated monitoring of PF may hold the potential to significantly improve patient health outcomes, enhance patient care, and lower the overall burden on clinicians managing patients with this disease. The wearable monitors previously discussed have the ability to continuously track physiological parameters (e.g., heart rate, oxygen saturation, coagulation status) as well as biochemical values (e.g., blood glucose, hemoglobin, blood lactate), offering live data that can notify clinicians of PF exacerbations and rapid patient decline [38]. Real-time monitoring allows immediate notification to the healthcare team and allows for crucial rapid response and implementation of life saving interventions [39]. This strategy allows clinicians to take a more proactive approach in the management of PF. Rather than reacting to patient decline or unanticipated exacerbations, clinicians can preemptively adjust treatment, such as fluids and antibiotic therapy, to mitigate PF-associated complications like DIC and septic shock.

The clinical applications of teleconsultation in the management and treatment of PF are highlighted by the ability for clinicians to rapidly receive specialist consultation and patients to receive specialist-level care in underserved and resource-limited settings. With complicated dermatological conditions, expert-level experience is needed for decision making. These remote resources hold the potential to save many patients' lives [40]. Telemedicine and teleconsultation overcome geographical barriers that hinder the implementation of specialized critical care [41]. AI-driven management and treatment resources further aid clinicians in decision making in complicated physiological parameters, such as hemodynamic management in septic shock or DIC [42]. Leveraging these technological advancements in clinical practice holds the potential to enhance patient monitoring and care delivery, better addressing the challenges associated with rapidly progressing diseases such as purpura fulminans.

Conclusion

The integration of telemedicine and remote monitoring technologies into the critical care management of purpura fulminans presents a transformative opportunity to enhance early detection, timely intervention, and overall patient outcomes. While traditional management strategies are limited by the rapid progression of PF and the need for specialized, in-person care, telemedicine offers a promising alternative by enabling continuous monitoring and rapid response through wearable sensors, real-time data analytics, and teleconsultation. However, realizing the full potential of this approach requires addressing several challenges, including the optimization of wearable sensor technology, the development of telehealth infrastructure, and comprehensive evaluations of cost-effectiveness and patient outcomes. While these challenges continue to be resolved, integrating telemedicine into PF management holds significant promise for better patient outcomes and reduced healthcare burdens. As technology and infrastructure evolve, telemedicine is poised to revolutionize PF care, enhancing early detection, timely treatment, and overall patient prognosis. Future research focused on these areas will be crucial in overcoming existing barriers and establishing telemedicine as a standard component of PF care, ultimately improving patient survival rates and reducing healthcare costs.

References

1. Edlich, R. F., Cross, C. L., Dahlstrom, J. J., & Long, W. B., 3rd (2008). Modern concepts of the diagnosis and treatment of purpura fulminans. Journal of environmental pathology, toxicology and oncology: official organ of the International Society for Environmental Toxicology and Cancer, 27(3), 191–196. https://doi.org/10.1615/jenvironpatholtoxicoloncol.v27.i3.30
2. Francis R. B., Jr (1990). Acquired purpura fulminans. *Seminars in thrombosis and hemostasis*, *16*(4), 310–325. https://doi.org/10.1055/s-2007-1002684
3. Chalmers, E., Cooper, P., Forman, K., Grimley, C., Khair, K., Minford, A., Morgan, M., & Mumford, A. D. (2011). Purpura fulminans: recognition, diagnosis and management. *Archives of disease in childhood*, *96*(11), 1066–1071. https://doi.org/10.1136/adc.2010.199919.
4. Dorsey, E. R., & Topol, E. J. (2020). Telemedicine 2020 and the next decade. *Lancet (London, England)*, *395*(10227), 859. https://doi.org/10.1016/S0140-6736(20)30424-4
5. Kumar, S., Merchant, S., & Reynolds, R. (2013). Tele-ICU: efficacy and cost-effectiveness of remotely managing critical care. *Perspectives in health information management*, *10*(Spring), 1f.
6. Majumder, S., Mondal, T., & Deen, M. J. (2017). Wearable Sensors for Remote Health Monitoring. *Sensors (Basel, Switzerland)*, *17*(1), 130. https://doi.org/10.3390/s17010130
7. Gu, L., & Lipner, S. R. (2022). Review of Telemedicine for Management of Acne Patients. *Journal of cutaneous medicine and surgery*, *26*(4), 393–397. https://doi.org/10.1177/12034754221083978
8. Hollander, J. E., & Carr, B. G. (2020). Virtually Perfect? Telemedicine for Covid-19. *The New England journal of medicine*, *382*(18), 1679–1681. https://doi.org/10.1056/NEJMp2003539
9. Scott Kruse, C., Karem, P., Shifflett, K., Vegi, L., Ravi, K., & Brooks, M. (2018). Evaluating barriers to adopting telemedicine worldwide: A systematic review. *Journal of telemedicine and telecare*, *24*(1), 4–12. https://doi.org/10.1177/1357633X16674087
10. Nolan, J., & Sinclair, R. (2001). Review of management of purpura fulminans and two case reports. *British journal of anaesthesia*, *86*(4), 581–586. https://doi.org/10.1093/bja/86.4.581
11. Levi, M., Toh, C. H., Thachil, J., & Watson, H. G. (2009). Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. British journal of haematology, 145(1), 24–33. https://doi.org/10.1111/j.1365-2141.2009.07600.x
12. Macheret, F., Pundi, K. N., Broomall, E. M., Davis, D. M., Rodriguez, V., & Brands, C. K. (2011). Empiric treatment of protracted idiopathic purpura fulminans in an infant: a case report and review of the literature. Journal of medical case reports, 5, 201. https://doi.org/10.1186/1752-1947-5-201
13. Lécuyer, H., Borgel, D., Nassif, X., & Coureuil, M. (2017). Pathogenesis of meningococcal purpura fulminans. Pathogens and disease, 75(3), 10.1093/femspd/ftx027. https://doi.org/10.1093/femspd/ftx027
14. Nasrullah, A., Javed, A., Tariq, U., Young, M., Moeen, Z., & Balaan, M. (2019). Purpura Fulminans: a Rare but Fierce Presentation of Pneumococcal Sepsis. European journal of case reports in internal medicine, 7(1), 001373. https://doi.org/10.12890/2019_001373
15. Yamagishi, T., Hikone, M., Sugiyama, K., Tanabe, T., Wada, Y., Furugaito, M., Arai, Y., Uzawa, Y., Mizushima, R., Kamada, K., Itakura, Y., Iguchi, S., Yoshida, A., Kikuchi, K., & Hamabe, Y. (2018). Purpura fulminans with Lemierre's syndrome caused by Gemella bergeri and Eikenella corrodens: a case report. BMC infectious diseases, 18(1), 523. https://doi.org/10.1186/s12879-018-3437-6
16. Vincent J. L. (2022). Current sepsis therapeutics. EBioMedicine, 86, 104318. https://doi.org/10.1016/j.ebiom.2022.104318
17. Eapen, Z. J., Turakhia, M. P., McConnell, M. V., Graham, G., Dunn, P., Tiner, C., Rich, C., Harrington, R. A., Peterson, E. D., & Wayte, P. (2016). Defining a Mobile Health Roadmap for Cardiovascular Health and Disease. Journal of the American Heart Association, 5(7), e003119. https://doi.org/10.1161/JAHA.115.003119
18. Mukherjee, D., Wang, P., Hooi, L., Sandhu, V., You, K., Blasiak, A., Chow, E. K., Ho, D., & Ee, P. L. R. (2022). Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria. Theranostics, 12(16), 6848–6864. https://doi.org/10.7150/thno.73078
19. Attallah, N., Hassan, E., Jama, A. B., Jain, S., Ellabban, M., Gleitz, R., Ali, S., Chand, M., Jain, N. K., & Khan, S. A. (2022). Management of Vasopressor-Induced Acute Limb Ischemia (VIALI) in Septic Shock. Cureus, 14(12), e33118. https://doi.org/10.7759/cureus.33118
20. Liu, Y., Chen, F., Bao, L., & Hai, W. (2022). Construction of a non-enzymatic electrochemical sensor based on graphitic carbon nitride nanosheets for sensitive detection of procalcitonin. RSC advances, 12(35), 22518–22525. https://doi.org/10.1039/d2ra03650a
21. Liu, L., Li, Y., Li, S., Hu, N., He, Y., Pong, R., Lin, D., Lu, L., & Law, M. (2012). Comparison of next-generation sequencing systems. Journal of biomedicine & biotechnology, 2012, 251364. https://doi.org/10.1155/2012/251364

22. Guo, H., Hildon, Z. J., & Chow, A. (2022). "Antibiotics are for everyone, our past and our future generations, right? If antibiotics are dead, we will be in big trouble": Building on community values for public engagement on appropriate use of antibiotics in Singapore. Frontiers in public health, 10, 1001282. https://doi.org/10.3389/fpubh.2022.1001282
23. Vural, B., Uludağ, İ., Ince, B., Özyurt, C., Öztürk, F., & Sezgintürk, M. K. (2023). Fluid-based wearable sensors: a turning point in personalized healthcare. Turkish journal of chemistry, 47(5), 944–967. https://doi.org/10.55730/1300-0527.3588
24. Levi, R., Carli, F., Arévalo, A. R., Altinel, Y., Stein, D. J., Naldini, M. M., Grassi, F., Zanoni, A., Finkelstein, S., Vieira, S. M., Sousa, J., Barbieri, R., & Celi, L. A. (2021). Artificial intelligence-based prediction of transfusion in the intensive care unit in patients with gastrointestinal bleeding. BMJ health & care informatics, 28(1), e100245. https://doi.org/10.1136/bmjhci-2020-100245
25. Ali, F., El-Sappagh, S., Islam, S. M. R., Ali, A., Attique, M., Imran, M., & Kwak, K. S. (2021). An intelligent healthcare monitoring framework using wearable sensors and social networking data. Future Generation Computer Systems, 114, 23-43. https://doi.org/10.1016/j.future.2020.07.047
26. Bingger, P., Zens, M., & Woias, P. (2012). Highly flexible capacitive strain gauge for continuous long-term blood pressure monitoring. Biomedical microdevices, 14(3), 573–581. https://doi.org/10.1007/s10544-012-9636-9
27. Chen, Y. Y., Lai, G. H., Chen, C. T., Cheng, H. C., & Tseng, S. H. (2024). Noninvasive hemoglobin quantification across different cohorts using a wearable diffuse reflectance spectroscopy system. Biomedical optics express, 15(3), 1739–1749. https://doi.org/10.1364/BOE.517645
28. Farooq, M., Iqbal, T., Vazquez, P., Farid, N., Thampi, S., Wijns, W., & Shahzad, A. (2020). Thin-Film Flexible Wireless Pressure Sensor for Continuous Pressure Monitoring in Medical Applications. Sensors (Basel, Switzerland), 20(22), 6653. https://doi.org/10.3390/s20226653
29. Feng, J., Zhang, C., Lischinsky, J. E., Jing, M., Zhou, J., Wang, H., Zhang, Y., Dong, A., Wu, Z., Wu, H., Chen, W., Zhang, P., Zou, J., Hires, S. A., Zhu, J. J., Cui, G., Lin, D., Du, J., & Li, Y. (2019). A Genetically Encoded Fluorescent Sensor for Rapid and Specific In Vivo Detection of Norepinephrine. Neuron, 102(4), 745–761.e8. https://doi.org/10.1016/j.neuron.2019.02.037
30. Komorowski, M., Celi, L. A., Badawi, O., Gordon, A. C., & Faisal, A. A. (2018). The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nature medicine, 24(11), 1716–1720. https://doi.org/10.1038/s41591-018-0213-5
31. Kvedar, J., Coye, M. J., & Everett, W. (2014). Connected health: a review of technologies and strategies to improve patient care with telemedicine and telehealth. *Health affairs (Project Hope)*, *33*(2), 194–199. https://doi.org/10.1377/hlthaff.2013.0992
32. Wootton R. (2001). Recent advances: Telemedicine. *BMJ (Clinical research ed.)*, *323*(7312), 557–560. https://doi.org/10.1136/bmj.323.7312.557
33. Young, L. B., Chan, P. S., Lu, X., Nallamothu, B. K., Sasson, C., & Cram, P. M. (2011). Impact of telemedicine intensive care unit coverage on patient outcomes: a systematic review and meta-analysis. *Archives of internal medicine*, *171*(6), 498–506. https://doi.org/10.1001/archinternmed.2011.61
34. Burke, B. L., Jr, Hall, R. W., & SECTION ON TELEHEALTH CARE (2015). Telemedicine: Pediatric Applications. *Pediatrics*, *136*(1), e293–e308. https://doi.org/10.1542/peds.2015-1517
35. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. *Nature*, *542*(7639), 115–118. https://doi.org/10.1038/nature21056
36. Topol E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. *Nature medicine*, *25*(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7
37. Harhay, M. O., Wagner, J., Ratcliffe, S. J., Bronheim, R. S., Gopal, A., Green, S., Cooney, E., Mikkelsen, M. E., Kerlin, M. P., Small, D. S., & Halpern, S. D. (2014). Outcomes and statistical power in adult critical care randomized trials. *American journal of respiratory and critical care medicine*, *189*(12), 1469–1478. https://doi.org/10.1164/rccm.201401-0056CP
38. Zhang, W., Sun, F., Lu, Z., Fan, S., Huang, Z., Hao, Y., Pan, Z., Chen, L., Lou, Y., & Liu, J. (2023). A wearable medical sensors system for in-situ monitoring vital signs of patients with hemorrhagic shock in big disaster scenes. *Sensors and Actuators B: Chemical*, *395*, 134448. https://doi.org/10.1016/j.snb.2023.134448
39. Joshi, M., Ashrafian, H., Aufegger, L., Khan, S., Arora, S., Cooke, G., & Darzi, A. (2019). Wearable sensors to improve detection of patient deterioration. *Expert Review of Medical Devices*, *16*(2), 145–154. https://doi.org/10.1080/17434440.2019.1563480
40. Patil, R., Shrivastava, R., Juvekar, S., McKinstry, B., & Fairhurst, K. (2021). Specialist to non-specialist teleconsultations in chronic respiratory disease management: A systematic review. *Journal of Global Health*, *11*. https://doi.org/10.7189/jogh.11.04019
41. Zanaboni, P., Scalvini, S., Bernocchi, P., Borghi, G., Tridico, C., & Masella, C. (2009). Teleconsultation service to improve healthcare in rural areas: Acceptance, organizational impact and appropriateness. *BMC Health Services Research*, *9*(1). https://doi.org/10.1186/1472-6963-9-238
42. Wu, M., Du, X., Gu, R., & Wei, J. (2021). Artificial Intelligence for clinical decision support in sepsis. *Frontiers in Medicine*, *8*. https://doi.org/10.3389/fmed.2021.665464

***Copyright: © 2024** Frasier K. This Open Access Article is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.*